Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CirDNA methylome analysis in prostate cancer

ABSTRACT: DNA modification profiling of circulating DNA (cirDNA) from plasma samples from prostate cancer patients (T2-3N0Mx), benign prostatic hyperplasia and control individuals Epigenetic differences are a common feature of many diseases, including cancer, and disease-associated changes have even been detected in bodily fluids. DNA modification studies in circulating DNA (cirDNA) may lead to the development of specific non-invasive biomarkers.

ORGANISM(S): Homo sapiens

PROVIDER: GSE36195 | GEO | 2012/07/10

SECONDARY ACCESSION(S): PRJNA152865

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

cirDNA methylome analysis in prostate cancer

Project description:DNA modification profiling of circulating DNA (cirDNA) from plasma samples from prostate cancer patients (T2-3N0Mx), benign prostatic hyperplasia and control individuals Epigenetic differences are a common feature of many diseases, including cancer, and disease-associated changes have even been detected in bodily fluids. DNA modification studies in circulating DNA (cirDNA) may lead to the development of specific non-invasive biomarkers. Three-conditions experiment: Prostate cancer (n=19), bening prostatic hyperplasia (n=20), controls without any know prostatic disease (n=20). cirDNA was isolated and the modified fraction of the genome was enriched using DNA-modification-sensitive digestion and adaptor-mediated PCR. Enriched fraction was labelled with Cy3. DNA samples extracted from white blood cells (WBC) of 20 individuals unrelated to this project were pooled and used as reference (Cy5-labelled).

2012-07-09 | E-GEOD-36195 | biostudies-arrayexpress

Genomic Analysis of Benign Prostatic Hyperplasia

Project description:Genomic Analysis of Benign Prostatic Hyperplasia

| PRJNA492376 | ENA

Genomic Analysis of Benign Prostatic Hyperplasia

Project description:Genomic Analysis of Benign Prostatic Hyperplasia

| PRJNA492375 | ENA

Spatial transcriptomic profiles of prostate tissue obtained from a patient diagnosed with benign prostatic hyperplasia (BPH).

Project description:ST profiles reveals the alterations in epithelial cells in Benign Prostatic Hyperplasia.

2024-05-01 | GSE242249 | GEO

CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis

Project description:To study the differential expression of genes in prostate cancer tissue and benign prostatic hyperplasia

2022-09-01 | GSE154075 | GEO

Combination of autoantibody signature with PSA level enables a highly accurate blood-based differentiation of prostate cancer patients from patients with benign prostatic hyperplasia

Project description:Although an increased level of the prostate-specific antigen can be an indication for prostate cancer, other reasons often lead to a high rate of false positive results. Therefore, an additional serological screening of autoantibodies in patients’ sera could improve the detection of prostate cancer. We performed protein macroarray screening with sera from 49 prostate cancer patients, 70 patients with benign prostatic hyperplasia and 28 healthy controls and compared the autoimmune response in those groups. We were able to distinguish prostate cancer patients from normal controls with an accuracy of 83.2%, patients with benign prostatic hyperplasia from normal controls with an accuracy of 86.0% and prostate cancer patients from patients with benign prostatic hyperplasia with an accuracy of 70.3%. Combining seroreactivity pattern with a PSA level of higher than 4.0 ng/ml this classification could be improved to an accuracy of 84.1%. For selected proteins we were able to confirm the differential expression by using Lluminex on 84 samples. We provide a minimally invasive serological method to reduce false positive results in detection of prostate cancer and according to PSA screening to distinguish men with prostate cancer from men with benign prostatic hyperplasia.

2017-02-10 | GSE67068 | GEO

Copy number analysis of BPH (Benign Prostatic Hyperplasia)

Project description:Copy number analysis of BPH (Benign Prostatic Hyperplasia)

| PRJNA510968 | ENA

Different expressed genes in epithelium and stromal of Benign Prostatic Hyperplasia

Project description:To identify the genes differently expressed in the epithelium and the stromal of Benign Prostatic Hyperplasia (BPH), we collect the epithelium and the stromal from the patients with benign prostatic hyperplasia by laser micro-dissection. And then, Affymetrix HG-U133_Plus_2 gene-chip was used to detect and compare the expression level of genes. To find which genes are most abundantly expressed in epithelium and stromal and what is the role of these genes in the pathogenesis of BPH.

2011-08-10 | GSE31323 | GEO

RNA sequencing and integrative analysis reveal pathways and hub genes associated with TGFβ1 stimulation on prostatic stromal cells (PrSCs)

Project description:To examine the effect of TGFβ1 on prostatic stromal cells, we firstly isolated primary prostatic stromal cells from five benign prostatic hyperplasia sample. Then RNA sequencing and bioinformatics analysis were used to reveal important pathways and hub genes associated with TGFβ1 stimulation on PrSCs.

2022-06-29 | GSE205378 | GEO

Comparative serum proteome profiling of canine benign prostatic hyperplasia before and after castration

Project description:Benign prostatic hyperplasia (BPH) is the most prevalent prostatic condition in older intact dogs; nonetheless, clinical diagnosis and management remain inconsistent. This study employed in-solution digestion coupled with nano-liquid chromatography-tandem mass spectrometry (nanoLC-MS/MS) to assess serum proteome profiling of dogs with BPH and those dogs after castration.

2024-10-11 | PXD046059 | JPOST Repository

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data